900257039 06/04/2013

TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
OncoGenex Technologies Inc.		05/05/2013	CORPORATION: CANADA

RECEIVING PARTY DATA

Name:	OncoGenex Pharmaceuticals, Inc.	
Street Address:	1522 217th Place SE	
Internal Address:	Suite 100	
City:	Bothell	
State/Country:	WASHINGTON	
Postal Code:	98021	
Entity Type:	CORPORATION: DELAWARE	

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Registration Number:	3886162	ONCOGENEX

CORRESPONDENCE DATA

Fax Number: 9702621809

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Phone: 970-262-1800

Email: docket@himtnpatents.com

Correspondent Name: Ryan E. Anderson Address Line 1: P.O. Box 4928

Address Line 4: Dillon, COLORADO 80435

ATTORNEY DOCKET NUMBER:	ONGX
NAME OF SUBMITTER:	Ryan E. Anderson
Signature:	/Ryan E. Anderson/
	TRADEMARK

TRADEMARK REEL: 005040 FRAME: 0979 P \$40,00 3886162

Date:	06/04/2013	
Total Attachments: 2 source=20130505_ExecutedAssignment#page1.tif source=20130505_ExecutedAssignment#page2.tif		

TRADEMARK
REEL: 005040 FRAME: 0980

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT ("Assignment") is from OncoGenex Technologies Inc., a Canadian corporation having a principal place of business at 400-1001 W. Broadway, Vancouver, B.C. V6H 4B1, CANADA (hereinafter referred to as "ASSIGNOR") to OncoGenex Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 1522 217th Place SE, Suite 100, Bothell, WA 98021 (hereinafter referred to as "ASSIGNEE").

WHEREAS, Assignor is the owner of all right, title and interest in US Trademark Registration Number 3,886,162 for the mark ONCOGENEX and US common law rights in the trademark ONCOGENEX, and in Canadian Trademark Registration Number 673,085 for the mark ONCOGENEX and Canadian common law rights in the trademark ONCOGENEX (collectively, the "Trademarks"), together with the goodwill of the business connected with and symbolized by the Trademarks;

WHEREAS, Assignee desires to acquire all right, title and interest in and to the Trademarks.

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are acknowledged, Assignor hereby agrees as follows.

Assignor hereby sells, assigns, transfers and conveys to Assignee the entire right, title, interest in and to the Trademarks, together with the goodwill of the business connected with and symbolized by the Trademarks (including, without limitation, the right to renew any registrations included in the Trademarks, the right to apply for trademark registrations within or outside the United States based in whole or in part upon the Trademarks, and any priority right that may arise from the Trademarks), the same to be held and enjoyed by Assignee as fully and entirely as said interest could have been held and enjoyed by Assignor had this sale, assignment, transfer and conveyance not been made.

Assignor authorizes the Commissioner of Trademarks of the United States and other empowered officials of the United States Patent and Trademark Office and in any applicable jurisdictions outside the United States to record the transfer of the registrations and/or applications for registration set forth on Exhibit 1 to Assignee as assignee of Assignor's entire right, title and interest therein. Assignor agrees to further execute any documents reasonably necessary to effect this assignment or to confirm Assignee's ownership of the Trademarks.

IN WITNESS WHEREOF, Assignor executes this Trademark Assignment to Assignee.

ASSIGNOR - OncoGenex Technologies Inc.

By: Scott D. CormackTitle: President and CEO

Date: May 5.20/3

ONGX.Gen (Trademark Assignment - ONCOGENEX)

IN WITNESS WHEREOF, Assignee accepts assignment of Trademarks.

ASSIGNEE - OncoGenex Pharmaceuticals, Inc.

By: Scott D. Cormack

Title: President and CEO

Date: May 5, 2013

ONGX.Gen (Trademark Assignment - ONCOGENEX)

RECORDED: 06/04/2013

TRADEMARK
REEL: 005040 FRAME: 0982